Терапевт - главная ›› Для врачей ›› Подагра
Подагра
1 . . .16 17 18 19 20 21 22
Rheumatology (Oxford). Feb 2009;48(2):188-94. [Medline].
Hair PI, McCormack PL, Keating GM. Febuxostat. Drugs. 2008;68(13):1865-74. [Medline].
Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. Sep 2008;58(9):2882-91. [Medline].
Becker MA, Schumacher HR Jr, Wortmann RL, et al. . A phase 3 study comparing the safety and efficacy of oral febuxostat and allopurinol in subjects with hyperuricemia and gout. Arthritis Rheum. 2004;50:4103-4..
Fam AG. Should patients with interval gout be treated with urate lowering drugs?. J Rheumatol. Sep 1995;22(9):1621-3. [Medline].
Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. Jun 1990;19(6):329-36. [Medline].
Konatalapalli RM, Demarco PJ, Jelinek JS, Murphey M, Gibson M, Jennings B, et al. Gout in the axial skeleton. J Rheumatol. Mar 2009;36(3):609-13. [Medline].
Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. Jan-Feb 2005;12(1):22-34. [Medline].
Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. May 20 2011;12:103.[Medline]
1 . . .16 17 18 19 20 21 22
comments powered by Disqus